SEC Form 4 · accession 0001209191-15-069431
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Tarriff
Officer — President and CEO · Director
Period of report
Sep 1, 2015
Accepted (ET)
Sep 3, 2015 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 1, 2015 | S | 2,526 | $77.93 | D | 1,518,386 | D | |
| Common StockF3 | Sep 1, 2015 | S | 11,792 | $76.88 | D | 1,506,594 | D | |
| Common StockF4 | Sep 1, 2015 | S | 1,878 | $76.09 | D | 1,504,716 | D | |
| Common Stock | Sep 1, 2015 | S | 49 | $75.12 | D | 1,504,667 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan dated as of June 19, 2015.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $77.50 to $78.45, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) and in footnote (3) and (4).
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $76.495 to $77.445, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $75.8301 to $76.38, inclusive